Pyrimidine-based compounds for the treatment of cancer

1. A compound of Formula:

or a pharmaceutically acceptable salt thereof;

wherein:

y is 0, 1, 2, 3, or 4;

Z is S, CH 2 , CHR 12 , CR 12 R 13 , NH, or NR 12 ;

represents the presence or absence of a double bond;

R is hydrogen, C 1 -C 6 alkyl, —(C 0 -C 2 alkyl)(C 3 -C 8 carbocyclyl), —(C 0 -C 2 alkyl)(C 3 -C 8 heterocyclyl),—(C 0 -C 2 alkyl)(aryl), —(C 0 -C 2 alkyl)(heteroaryl), —COOalkyl, —COOarylalkyl, or —COOH;

each R 1 is independently at each occurrence selected from the group consisting of alkyl, aryl, cycloalkyl, and haloalkyl, wherein each of said alkyl, cycloalkyl and haloalkyl groups optionally includes heteroatoms O, N, or S in place of a carbon in the chain and two R 1 s on adjacent ring atoms or on the same ring atom together with the ring atom(s) to which they are attached optionally form a 3-8-membered cycle;

wherein the 3-8 membered cycle formed by combining two R 1 s with the atom(s) to which they are attached can be either a carbocycle or a heterocycle;

and wherein the 3-8 membered cycle formed by combining two R 1 s with the atom(s) to which they are attached can be optionally substituted with one or more substituents selected from the group consisting of amino, —NHR 14 , —NR 14 R 15 , hydroxyl, OR 14 , R 6 , and R 2 ;

R 7 is selected from the group consisting of:

or R 7 is selected from the group consisting of cycloalkyl, heterocycle, and alkyl, each of which cycloalkyl, heterocycle, and alkyl groups is optionally substituted with one or more substituents selected from the group consisting of amino, —NHR 14 , —NR 14 R 15 , hydroxyl, OR 14 , R 6 , and R 2 ;

X 1 , X 2 , X 3 , X 4 , and X 5 are independently N or CR 8 , wherein at least one of X 1 , X 2 , X 3 , X 4 , and X 5 are CR 8 ;

R 8 is independently at each instance selected from the group consisting of R 6 and R 2 , wherein one R 8 is R 2 ;

R 2 is independently selected from the group consisting of -(alkylene) m -heterocyclo, -(alkylene) m -hetero aryl, -(alkylene) m -NR 3 R 4 , -(alkylene) m -C(O)—NR 3 R 4 ; -(alkylene) m -C(O)—O-alkyl; -(alkylene) m -O—R 5 , -(alkylene) m -S(O) n —R 5 , and -(alkylene) m -S(O) n —NR 3 R 4 ; any of which may be optionally independently substituted with one or more R x groups as allowed by valance, and wherein two R x groups bound to the same or adjacent atom may optionally combine to form a ring;

m is 0 or 1;

n is 0, 1 or 2;

R 3 and R 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, arylalkyl, and heteroarylalkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached may combine to form a heterocyclo ring;

R 5 is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, arylalkyl, and heteroarylalkyl;

R x at each occurrence is independently selected from the group consisting of halo, cyano, nitro, oxo, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, -(alkylene) m -OR 5 , -(alkylene) m -O-alkylene-OR 5 , -(alkylene) m -S(O) n —R 5 , -(alkylene) m -NR 3 R 4 , -(alkylene) m -CN, -(alkylene) m -C(O)—R 5 , -(alkylene) m -C(S)—R 5 , -(alkylene) m -C(O)—OR 5 , -(alkylene) m -O—C(O)—R 5 , -(alkylene) m -C(S)—OR 5 , -(alkylene) m -C(O)-(alkylene) m -NR 3 R 4 , -(alkylene) m -C(S)—NR 3 R 4 , -(alkylene) m -N(R 3 )—C(O)—NR 3 R 4 , -(alkylene) m -N(R 3 )—C(S)—NR 3 R 4 , -(alkylene) m -N(R 3 )—C(O)—R 5 , -(alkylene) m -N(R 3 )—C(S)—R 5 , -(alkylene) m -O—C(O)—NR 3 R 4 , -(alkylene) m -O—C(S)—NR 3 R 4 , -(alkylene) m -SO 2 —NR 3 R 4 , -(alkylene) m -N(R 3 )—SO 2 —R 5 , -(alkylene) m -N(R 3 )—SO 2 —NR 3 R 4 , -(alkylene) m -N(R 3 )—C(O)—OR 5 , -(alkylene) m -N(R 3 )—C(S)—OR 5 , and -(alkylene) m -N(R 3 )—SO 2 —R 5 ,

R 6 is independently at each instance selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, arylalkyl, and heteroarylalkyl;

R 10 and R 11 are selected from the group consisting of hydrogen, alkyl, —NH 2 , —NHR 12 , —NR 12 R 13 , —S(O)alkyl, and —SO 2 alkyl;

or R 10 and R 11 are selected from the group consisting of cycloalkyl, heterocycle, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted with one or more substituents selected from the group consisting of amino, —NHR 14 , —NR 14 R 15 , hydroxyl, OR 14 , R 6 , and R 2 ;

R 12 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, —C(O)H, —C(O)alkyl, —C(S)alkyl, aryl, —SO 2 alkyl, heteroaryl, arylalkyl, and heteroarylalkyl;

or R 12 is selected from the group consisting of cycloalkyl, heterocycle, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted with one or more substituents selected from the group consisting of amino, —NHR 14 , —NR 14 R 15 , hydroxyl, OR 14 , R 6 , and R 2 ;

R 13 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, —C(O)H, —C(O)alkyl, —C(S)alkyl, aryl, —SO 2 alkyl, heteroaryl, arylalkyl, and heteroarylalkyl;

or R 13 is selected from the group consisting of cycloalkyl, heterocycle, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted with one or more substituents selected from the group consisting of amino, —NHR 14 , —NR 14 R 15 , hydroxyl, OR 14 , R 6 , and R 2 ; and

R 14 and R 15 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, —C(O)H, —C(O)alkyl, —C(S)alkyl, aryl, —SO 2 alkyl, heteroaryl, arylalkyl, and heteroarylalkyl.

2. The compound of claim 1 , wherein y is 0.

3. The compound of claim 1 , wherein y is 1.

4. The compound of claim 1 , wherein y is 2.

5. The compound of claim 4 , wherein two R 1 groups on adjacent ring atoms or on the same ring atom together with the ring atom(s) to which they are attached optionally form a 3-8-membered cycle.

6. The compound of claim 5 , wherein the 3-8-membered cycle is a 6-membered cycle.

7. The compound of claim 6 , wherein R 2 is:

8. The compound of claim 1 , wherein R 2 is heterocyclo optionally independently substituted with one or more R x groups as allowed by valance.

9. The compound of claim 8 , wherein R x at each occurrence is independently selected from the group consisting of halo, cyano, nitro, oxo, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkyl.

10. The compound of claim 1 wherein R 2 is:

11. The compound of claim 1 , wherein m is 0.

12. The compound of claim 1 , wherein n is 0.

13. The compound of claim 1 , wherein R 3 and R 4 are hydrogen.

14. The compound of claim 1 , wherein R 5 is alkyl.

15. The compound of claim 1 , wherein R 7 is

16. The compound of claim 15 , wherein R 2 is heterocyclo optionally independently substituted with one or more R x groups as allowed by valance.

17. The compound of claim 16 , wherein R x at each occurrence is independently selected from the group consisting of halo, cyano, nitro, oxo, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkyl.

18. The compound of claim 1 selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

20. A method for the treatment of abnormal cellular proliferation comprising administering an effective amount to a host in need thereof of a compound of claim 1 , optionally in a pharmaceutically acceptable carrier.